114 related articles for article (PubMed ID: 8760603)
1. Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A.
Warnier G; Duffour MT; Uyttenhove C; Gajewski TF; Lurquin C; Haddada H; Perricaudet M; Boon T
Int J Cancer; 1996 Jul; 67(2):303-10. PubMed ID: 8760603
[TBL] [Abstract][Full Text] [Related]
2. CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A.
Rosato A; Zambon A; Milan G; Ciminale V; D'Agostino DM; Macino B; Zanovello P; Collavo D
Hum Gene Ther; 1997 Aug; 8(12):1451-8. PubMed ID: 9287145
[TBL] [Abstract][Full Text] [Related]
3. Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815.
Bilsborough J; Van Pel A; Uyttenhove C; Boon T; Van den Eynde BJ
J Immunol; 1999 Mar; 162(6):3534-40. PubMed ID: 10092811
[TBL] [Abstract][Full Text] [Related]
4. Localization of two cytotoxic T lymphocyte epitopes and three anchoring residues on a single nonameric peptide that binds to H-2Ld and is recognized by cytotoxic T lymphocytes against mouse tumor P815.
Van den Eynde B; Mazarguil H; Lethé B; Laval F; Gairin JE
Eur J Immunol; 1994 Nov; 24(11):2740-5. PubMed ID: 7525302
[TBL] [Abstract][Full Text] [Related]
5. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene.
Colmenero P; Liljeström P; Jondal M
Gene Ther; 1999 Oct; 6(10):1728-33. PubMed ID: 10516722
[TBL] [Abstract][Full Text] [Related]
6. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice.
Van den Eynde B; Lethé B; Van Pel A; De Plaen E; Boon T
J Exp Med; 1991 Jun; 173(6):1373-84. PubMed ID: 1903428
[TBL] [Abstract][Full Text] [Related]
7. Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815.
Brichard VG; Warnier G; Van Pel A; Morlighem G; Lucas S; Boon T
Eur J Immunol; 1995 Mar; 25(3):664-71. PubMed ID: 7705394
[TBL] [Abstract][Full Text] [Related]
8. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG
Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039
[TBL] [Abstract][Full Text] [Related]
9. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide.
Lethé B; van den Eynde B; van Pel A; Corradin G; Boon T
Eur J Immunol; 1992 Sep; 22(9):2283-8. PubMed ID: 1381312
[TBL] [Abstract][Full Text] [Related]
10. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor.
Näslund TI; Uyttenhove C; Nordström EK; Colau D; Warnier G; Jondal M; Van den Eynde BJ; Liljeström P
J Immunol; 2007 Jun; 178(11):6761-9. PubMed ID: 17513723
[TBL] [Abstract][Full Text] [Related]
11. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones.
Maryanski JL; Boon T
Eur J Immunol; 1982 May; 12(5):406-12. PubMed ID: 6178608
[TBL] [Abstract][Full Text] [Related]
12. The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen.
Uyttenhove C; Godfraind C; Lethé B; Amar-Costesec A; Renauld JC; Gajewski TF; Duffour MT; Warnier G; Boon T; Van den Eynde BJ
Int J Cancer; 1997 Jan; 70(3):349-56. PubMed ID: 9033639
[TBL] [Abstract][Full Text] [Related]
13. Differential resistance to growth of a tumor expressing incompatible minor alloantigens reflects regulatory influences rather than differences in anti-minor-CTL-P frequencies.
Carayanniotis G; Halloran PF
Cell Immunol; 1985 Mar; 91(1):100-10. PubMed ID: 2857596
[TBL] [Abstract][Full Text] [Related]
14. Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the p815 murine tumor.
Levraud JP; Pannetier C; Langlade-Demoyen P; Brichard V; Kourilsky P
J Exp Med; 1996 Feb; 183(2):439-49. PubMed ID: 8627157
[TBL] [Abstract][Full Text] [Related]
15. The constitutive expression of the immunomodulatory gp19k protein in E1-, E3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector.
Lee MG; Abina MA; Haddada H; Perricaudet M
Gene Ther; 1995 Jun; 2(4):256-62. PubMed ID: 7552985
[TBL] [Abstract][Full Text] [Related]
16. [Xenogeneic melanoma-related antigen elicits anti-tumor immune response, companied by autoimmune injury].
Tan XH; Wan YH
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(23):1596-600. PubMed ID: 16185524
[TBL] [Abstract][Full Text] [Related]
17. CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide.
Grohmann U; Bianchi R; Fioretti MC; Fallarino F; Binaglia L; Uyttenhove C; Van Pel A; Boon T; Puccetti P
Eur J Immunol; 1995 Oct; 25(10):2797-802. PubMed ID: 7589074
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors.
Song W; Kong HL; Traktman P; Crystal RG
Hum Gene Ther; 1997 Jul; 8(10):1207-17. PubMed ID: 9215738
[TBL] [Abstract][Full Text] [Related]
19. Co-expression of P1A35-43/beta2m fusion protein and co-stimulatory molecule CD80 elicits effective anti-tumor immunity in the P815 mouse mastocytoma tumor model.
Zhang X; Mei W; Zhang L; Yu H; Zhao X; Fan X; Qian G; Ge S
Oncol Rep; 2009 Nov; 22(5):1213-20. PubMed ID: 19787242
[TBL] [Abstract][Full Text] [Related]
20. Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL.
Silla S; Fallarino F; Boon T; Uyttenhove C
Eur Cytokine Netw; 1999 Jun; 10(2):181-90. PubMed ID: 10400824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
